Reported Saturday, BioMarin's VOXZOGO Demonstrates Proportional Skeletal Growth And Maintained Bone Density Over Six Years In Achondroplasia Children At PES Meeting

VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia

Researchers will present additional data from studies of VOXZOGO for hypochondroplasia, ahead of pivotal topline Phase 3 data expected in the first half of 2026